About the Study

Nasopharyngeal carcinoma (NPC): A study using nivolumab in combination with chemotherapy drugs

This study is for children and young adults: • 21 years old and younger • Who have nasopharyngeal carcinoma (NPC) The overall goal of this study is to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on people with newly diagnosed NPC. In addition, researchers want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.

Interested in learning more?

Full Study Name: ARAR2221 - A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)